Has the role of EUS in rectal cancer staging changed in the last decade?

Angad Singh Uberoi, Manoop S. Bhutani
University of Texas MD Anderson Cancer Center Houston, Houston, Texas, USA

ABSTRACT
The need for effective diagnosis, staging, and treatment of rectal cancer cannot be overstated. Accurate staging of rectal cancer has wide-ranging implications, including therapeutic strategy and prognosis. A change in stage may lead to the need for preoperative neoadjuvant therapy to decrease the risk of recurrence. The modalities commonly used for the primary staging of rectal cancer include EUS, computed tomography, and magnetic resonance imaging. EUS may be accompanied by the use of EUS-fine-needle aspiration to provide cytological confirmation. In this review, we take a deeper look into the role of EUS in the accurate staging of rectal cancer, how it compares to other modalities for the same, and how its role has changed in the last decade.

Key words: EUS, magnetic resonance imaging scan, magnetic resonance imaging, rectal cancer, staging

INTRODUCTION

According to the American Cancer Society, 39,910 new cases of rectal cancer will be diagnosed in the United States in 2017.[1] Colorectal cancer is the third most common cancer diagnosed in both men and women.[1] Thus, the need for effective diagnosis, staging, and treatment of rectal cancer cannot be overstated. Accurate staging of rectal cancer has wide-ranging implications. Foremost is the choice of treatment strategy offered, which changes drastically with a change in the clinical stage of the patient.[2] While early lesions (cT1N0M0) with minimal invasion may be effectively treated with local resection with endoscopic polypectomy or transanal endoscopic microsurgery, cT2-4 disease requires more extensive surgery with total mesorectal excision (TME). In this category, a subset of patients requires preoperative neoadjuvant therapy with chemoradiation (cT3-4 or node-positive disease). Staging also gives important information regarding patient prognosis. Thus, accurate staging is the foundation on which an effective management plan for rectal cancer is built. Multiple modalities have been used for staging rectal cancer – computerized tomography (CT), magnetic resonance imaging (MRI), positron emission tomography, and EUS.[3] In this review, we take a deeper look into the role of EUS in the accurate staging of rectal cancer, and how this role has changed over the course of the last decade.

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

Address for correspondence
Dr. Manoop S. Bhutani, University of Texas MD Anderson Cancer Center Houston, Houston, Texas, USA.
E-mail: manoop.bhutani@mdanderson.org
Received: 2017-09-02; Accepted: 2018-08-09; Published online: 2018-12-06
EUS FOR T-STAGING OF RECTAL CANCER

The normal appearance of the rectum on EUS is an echo pattern which consists of five layers. The first and second layers correspond to the rectal mucosa, the third layer corresponds to the submucosa, the fourth layer is the muscularis propria, and the outermost layer is the adventitia. Rectal cancers are seen on EUS as hypoechoic masses which are seen to disrupt this normal echo pattern of the rectum. T1 lesions are limited to the mucosa and submucosa and thus do not extend beyond the first three echo layers seen on EUS. T2 lesions are seen to extend up to but not penetrate through the fourth hypoechoic layer (which corresponds to the muscularis propria). T3 lesions invade through the muscularis and may even extend beyond the five echo layers into the perirectal space. A T4 lesion invades the visceral peritoneum or involves the adjacent organs such as the prostate, bladder, seminal vesicles, or vagina.

The accuracy of EUS for T-staging in reports has varied from as low as 63% up to a highest report of 96%.[4,5] In the largest meta-analysis to date, Puli et al. evaluated data from 42 studies (N = 5039) which compared EUS T-stage with that determined by surgical histopathology.[6] The authors calculated the pooled sensitivity and specificity of EUS to be 87.8% (95% confidence interval [CI]: 85.3%–90.0%) and 98.3% (95% CI: 97.8%–98.7%), respectively, for T1 lesions; 80.5% (95% CI: 77.9%–82.0%) and 95.6% (95% CI: 94.9%–96.3%), respectively, for T2 lesions; 96.4% (95% CI: 95.4%–97.2%) and 90.6% (95% CI: 89.5%–91.7%), respectively, for T3 lesions; and 95.4% (95% CI: 92.4%–97.5%) and 98.3% (95% CI: 97.8%–98.7%), respectively, for T4 cancer. The authors concluded that EUS is accurate for the T-staging of rectal cancer.

These findings have not been supported by subsequent reviews. Marusch et al. conducted a large, prospective study which looked at data from more than 300 centers in Germany (N = 7096) to analyze the accuracy of EUS in staging rectal cancer in routine clinical practice.[7] This was done by calculating the degree of correspondence between EUS assessed T-stage (uT) and the T-stage on histopathological examination (pT). The value of this correspondence was calculated by the authors to be 64.7% (95% CI: 63.6%–65.8%). Of the 35.3% of cases, when the T-stage was not found to correspond, 18% (95% CI: 17.1%–18.9%) was due to understaging by EUS and 17.3% (95% CI: 16.4%–18.2%) was due to the EUS overstaging cancer. T2 and T4 lesions were reported to have a lower rate of correlation between EUS and histopathological T-stage than T1 and T3 lesions. This study also sought to compare the hospital EUS volume with the degree of uT-pT correspondence. It was seen that uT-pT correspondence was 63.2% (95% CI: 61.5%–64.9%) for centers which performed ≤10 EUS per year, 64.6% (95% CI: 62.9%–66.2%) for those performing 11–30 EUS per year, and 73.1% (95% CI: 69.4%–76.5%) for those with a EUS caseload of >30 per year. Thus, it was hypothesized that EUS in routine clinical practice does not match the accuracy reported in literature and that accuracy of EUS improved with greater experience and volume of cases performed in the center.

While any change in T-stage has significance to patient prognosis, a change in T-stage at the threshold for primary surgical resection (without the need for neoadjuvant therapy) has enormous implications in patient management. Ahuja et al. aimed to assess the accuracy of EUS at this important branch point in therapeutic strategy by calculating the negative predictive value (NPV) of EUS for T2 disease.[8] As pT1 lesions overstaged as uT2 would not have any effect on the treatment strategy (no need for neoadjuvant therapy), while any change in T-stage above T2 has significance to patient prognosis, a change in T-stage at the threshold for primary surgical resection (without the need for neoadjuvant therapy) has enormous implications in patient management. Ahuja et al. aimed to assess the accuracy of EUS at this important branch point in therapeutic strategy by calculating the negative predictive value (NPV) of EUS for T2 disease.[8] As pT1 lesions overstaged as uT2 would not have any effect on the treatment strategy (no need for neoadjuvant therapy), while any change in T-stage above T2 has significance to patient prognosis, a change in T-stage at the threshold for primary surgical resection (without the need for neoadjuvant therapy) has enormous implications in patient management. Ahuja et al. aimed to assess the accuracy of EUS at this important branch point in therapeutic strategy by calculating the negative predictive value (NPV) of EUS for T2 disease.[8] As pT1 lesions overstaged as uT2 would not have any effect on the treatment strategy (no need for neoadjuvant therapy), while any change in T-stage above T2 has significance to patient prognosis, a change in T-stage at the threshold for primary surgical resection (without the need for neoadjuvant therapy) has enormous implications in patient management. Ahuja et al. aimed to assess the accuracy of EUS at this important branch point in therapeutic strategy by calculating the negative predictive value (NPV) of EUS for T2 disease.[8] As pT1 lesions overstaged as uT2 would not have any effect on the treatment strategy (no need for neoadjuvant therapy), while any change in T-stage above T2 has significance to patient prognosis, a change in T-stage at the threshold for primary surgical resection (without the need for neoadjuvant therapy) has enormous implications in patient management. Ahuja et al. aimed to assess the accuracy of EUS at this important branch point in therapeutic strategy by calculating the negative predictive value (NPV) of EUS for T2 disease.[8] As pT1 lesions overstaged as uT2 would not have any effect on the treatment strategy (no need for neoadjuvant therapy), while any change in T-stage above T2 has significance to patient prognosis, a change in T-stage at the threshold for primary surgical resection (without the need for neoadjuvant therapy) has enormous implications in patient management. Ahuja et al. aimed to assess the accuracy of EUS at this important branch point in therapeutic strategy by calculating the negative predictive value (NPV) of EUS for T2 disease.[8] As pT1 lesions overstaged as uT2 would not have any effect on the treatment strategy (no need for neoadjuvant therapy), while any change in T-stage above T2 has significance to patient prognosis, a change in T-stage at the threshold for primary surgical resection (without the need for neoadjuvant therapy) has enormous implications in patient management. Ahuja et al. aimed to assess the accuracy of EUS at this important branch point in therapeutic strategy by calculating the negative predictive value (NPV) of EUS for T2 disease.[8] As pT1 lesions overstaged as uT2 would not have any effect on the treatment strategy (no need for neoadjuvant therapy), while any change in T-stage above T2 has significance to patient prognosis, a change in T-stage at the threshold for primary surgical resection (without the need for neoadjuvant therapy) has enormous implications in patient management. Ahuja et al. aimed to assess the accuracy of EUS at this important branch point in therapeutic strategy by calculating the negative predictive value (NPV) of EUS for T2 disease.[8] As pT1 lesions overstaged as uT2 would not have any effect on the treatment strategy (no need for neoadjuvant therapy), while any change in T-stage above T2 has significance to patient prognosis, a change in T-stage at the threshold for primary surgical resection (without the need for neoadjuvant therapy) has enormous implications in patient management. Ahuja et al. aimed to assess the accuracy of EUS at this important branch point in therapeutic strategy by calculating the negative predictive value (NPV) of EUS for T2 disease.[8] As pT1 lesions overstaged as uT2 would not have any effect on the treatment strategy (no need for neoadjuvant therapy), while any change in T-stage above T2 has significance to patient prognosis, a change in T-stage at the threshold for primary surgical resection (without the need for neoadjuvant therapy) has enormous implications in patient management. Ahuja et al. aimed to assess the accuracy of EUS at this important branch point in therapeutic strategy by calculating the negative predictive value (NPV) of EUS for T2 disease.[8] As pT1 lesions overstaged as uT2 would not have any effect on the treatment strategy (no need for neoadjuvant therapy), while any change in T-stage above T2 has significance to patient prognosis, a change in T-stage at the threshold for primary surgical resection (without the need for neoadjuvant therapy) has enormous implications in patient management. Ahuja et al. aimed to assess the accuracy of EUS at this important branch point in therapeutic strategy by calculating the negative predictive value (NPV) of EUS for T2 disease.[8] As pT1 lesions overstaged as uT2 would not have any effect on the treatment strategy (no need for neoadjuvant therapy), while any change in T-stage above T2 has significance to patient prognosis, a change in T-stage at the threshold for primary surgical resection (without the need for neoadjuvant therapy) has enormous implications in patient management. Ahuja et al. aimed to assess the accuracy of EUS at this important branch point in therapeutic strategy by calculating the negative predictive value (NPV) of EUS for T2 disease.[8] As pT1 lesions overstaged as uT2 would not have any effect on the treatment strategy (no need for neoadjuvant therapy), while any change in T-stage above T2 has significance to patient prognosis, a change in T-stage at the threshold for primary surgical resection (without the need for neoadjuvant therapy) has enormous implications in patient management. Ahuja et al. aimed to assess the accuracy of EUS at this important branch point in therapeutic strategy by calculating the negative predictive value (NPV) of EUS for T2 disease.[8] As pT1 lesions overstaged as uT2 would not have any effect on the treatment strategy (no need for neoadjuvant therapy), while any change in T-stage above T2 has significance to patient prognosis, a change in T-stage at the threshold for primary surgical resection (without the need for neoadjuvant therapy) has enormous implications in patient management. Ahuja et al. aimed to assess the accuracy of EUS at this important branch point in therapeutic strategy by calculating the negative predictive value (NPV) of EUS for T2 disease.[8] As pT1 lesions overstaged as uT2 would not have any effect on the treatment strategy (no need for neoadjuvant therapy), while any change in T-stage above T2 has significance to patient prognosis, a change in T-stage at the threshold for primary surgical resection (without the need for neoadjuvant therapy) has enormous implications in patient management.

EUS FOR N-STAGING OF RECTAL CANCER

The N-staging of rectal cancer is determined by assessing the perirectal lymph nodes for changes seen in malignant infiltration. A thorough lymph node survey is performed from the anal verge up to the level of the iliac vessels approximately 25–30 cm from the dentate line. These nodes are usually round and hypoechoic and have a regular border. Although various studies have described different size cutoffs for malignant lymph nodes, any node seen in a patient with rectal cancer should be closely assessed for malignancy as EUS does not normally visualize lymph nodes in the perirectal region.[9,10] The presence of 1–3 malignant appearing
nodes is considered as N1 disease and 4 or more nodes as N2 disease.

Puli et al. conducted a meta-analysis to determine the accuracy of EUS for the N-staging of rectal cancer (N = 2732). They determined the pooled sensitivity of this modality to be 73.2% (95% CI: 70.6%–75.6%) and pooled specificity to be 75.8% (95% CI: 73.5%–78.0%). The positive likelihood ratio was 2.84 (95% CI: 2.16%–3.72%) and negative likelihood ratio was 0.42 (95% CI: 0.33%–0.52%). Comparing the modest positive likelihood ratio to the low-negative likelihood ratio, the authors concluded that EUS had more utility in excluding nodal invasion rather than confirming the presence of node-positive disease.

Gleeson et al. performed a prospective study to assess the accuracy of the conventionally used echo features of lymph nodes (hypoechoic, round, smooth borders, short axis ≥10 mm), along with nodal dimensions to predict malignant invasion of lymph nodes. This study also aimed to assess if a cutoff or threshold number of positive criteria could be used to accurately predict the involvement of lymph nodes. The results of this study showed that only two nodal features could adequately predict malignancy: short-axis length ≥5 mm (odds ratio = 2.7; 95% CI: 1.3%–6.1%; P = 0.009) and hypoechogenic appearance (odds ratio = 3.8; 95% CI: 1.4%–13.8%; P = 0.017). The nodal dimensions with the highest accuracy were short axis of 6 mm (sensitivity 59%, specificity 90%) and long axis of 9 mm (sensitivity 46%, specificity 95%). The authors also concluded that a threshold number of positive echo criteria would not be feasible to predict nodal disease as only the presence of all four criteria could reliably identify an involved node, which was seen only in 23% of cases. Another challenge in the identification of nodes with EUS is the inability to visualize nodes that are outside the range of the transducer. Thus, N-staging of rectal cancer remains to be an area of uncertainty.

EUS-FNA

EUS-FNA may be used in addition to visual characteristics of lymph nodes to accurately identify nodal involvement in rectal cancer. While it theoretically provides the prospect of increased accuracy due to the cytological confirmation of malignant changes, various reports have had conflicting results. Some reports have asserted that EUS-FNA is a useful tool for the accurate staging of rectal cancer and can improve the accuracy of EUS alone for nodal staging. The use of EUS-FNA in the staging of rectal cancer patients was associated with a reduced recurrence risk as compared to staging by CT scan. In another report, Harewood et al. reported that the addition of FNA did not significantly change management in patients who were N-staged with radiographic characteristics alone. This was due to the fact that in patients with T3 or more advanced lesions, the detection of previously undiagnosed nodal disease would not alter therapeutic strategy as these patients would receive neoadjuvant chemoradiation regardless of N-stage. EUS-FNA has more utility in early T-stages (T1/ T2) where the presence of involved nodes would upstage the disease and change the management of the patient. Furthermore, it is of note that EUS-FNA cannot be performed in those cases where sampling of nodes would require passage of the needle through the primary tumor (i.e., peritumoral nodes) as this would lead to a high false-positive rate, along with the possibility of potential seeding of nodes with malignant cells.

EUS VERSUS COMPUTERIZED TOMOGRAPHY AND MAGNETIC RESONANCE IMAGING

Bipat et al. performed a meta-analysis in 2004 to compare the accuracy of EUS, CT, and MRI for the staging of rectal cancer. The authors reported that EUS was superior to CT and MRI for the T-staging of rectal cancer and comparable to these modalities for N-staging. However, with the advent of newer developments in MRI technology such as the endorectal coil, phased-array surface coil, and 3.0T MRI, the accuracy of this modality for the T-staging of rectal cancer has vastly improved. Specifically, MRI has been proven to be the most accurate modality for the prediction of the involvement of the circumferential resection margin (CRM), which is an extremely important prognostic factor as well as important in the surgical planning before TME. Thus, MRI is preferred over EUS in locally advanced cases (T3/T4) which require a more detailed evaluation of the resection plane and the CRM. MRI also has more utility over EUS in stenotic lesions where the EUS probe may not be passed across the lesion. On the other hand, MRI is inferior to EUS for early lesions as differentiating between T1 and T2 lesions is challenging.
with MRI due to limited visualization of the rectal submucosa.[18,25] This may be of importance in choosing the resection strategy in early cases. Furthermore, polypoid morphology of the tumor is associated with decreased accuracy of MRI for T-staging.[24] Thus, choosing the appropriate imaging modality has to take multiple factors into consideration, including clinical picture, availability of experienced personnel, treatment strategy, and cost. CT scanning plays an important role in the assessment of systemic spread of rectal cancer and has a limited role in locoregional staging.

While literature suggests that EUS and MRI are comparable for the staging of rectal cancer, in the author's (MSB) personal experience at a tertiary cancer center in the developed world, the number of cases referred by colorectal surgeons and oncologists for staging by EUS has steadily declined over the past decade. This may be attributed to several factors. The primary reason is the advantages of high-quality latest generation MRI for determination of CRM, surgical planning, and providing T-stage information for T3/T4 cases. Only selected cases are referred now when after the MRI, determination of T1/T2 stage is needed, or there is a node seen on MRI, EUS-FNA of which is desired by the surgical or medical/radiation oncologists. While improvements in MRI technology have made it comparable or even superior to EUS in certain clinical circumstances, it is also a more convenient option in many practical settings. The availability of sufficiently experienced personnel for EUS may be a limiting factor in many practices, whereas radiology services may be more widely available. Furthermore, MRI is less invasive for the patient while EUS involves some degree of discomfort. However, there may be countries and hospitals where newer MRI technology is not available, but there is an experienced endosonographer who performs rectal EUS routinely, and EUS may be a better option there. Thus, the decision is not straightforward and must take into account the variables above.

ROLE OF EUS IN RESTAGING AFTER CHEMOTHERAPY AND RADIATION

Restaging of locally advanced rectal cancer after neoadjuvant chemoradiation is useful to tailor therapeutic strategy, allowing patients with good response to forego the morbidity and loss of function associated with more extensive procedures. However, multiple studies have reported that for this purpose, EUS lacks the accuracy it shows in primary staging.[26-31] Changes seen in the peritumoral region because of the effects of chemoradiation such as edema, inflammation, necrosis, and fibrosis lead to a hypoechoic appearance which mimics the primary tumor, leading to frequent overstaging. Thus, EUS is not generally recommended in the routine restaging of rectal cancer after preoperative therapy.

ENHANCED EUS TECHNIQUES FOR RECTAL CANCER

EUS elastography is an enhanced technique which can be utilized to quantify the relative elasticity or hardness of tissues, which in turn allows us to differentiate and delineate benign areas (more elastic) from malignant areas (less elastic). Software applications can be used to quantify these data by either forming color-coded histograms or calculating a strain ratio by comparing elasticity of a particular region of interest with a reference value. While studies have shown that elastography can be an effective modality to differentiate benign rectal adenomas from malignant tumors, the exact role of this technique in the staging of rectal cancer is yet to be studied and reported.[32]

Contrast-enhanced EUS is another development which has been used to visualize and quantify tumor vascularity. This is done with the help of microbubbles which are used as intravenous ultrasound contrast agents and estimation of perfusion levels with the help of objective parameters such as area under the curve in the time-intensity curve. While this data can be used to assess response to antiangiogenic therapy, the routine application of this modality for the staging of rectal cancer is not yet mainstream and standardized.[33]

CONCLUSION

Accurate staging of rectal cancer is essential to make appropriate therapeutic decisions. EUS is accurate for the locoregional staging of these patients and has been shown to perform favorably as compared to other modalities for early lesions. Performance of EUS depends on the experience of personnel and the volume of cases performed at the center, leading to real-world results which may not match those reported in literature in the hands of less experienced endosonographers. Selection of staging modality should be individualized according to the clinical picture, and
the use of EUS may be complemented with the use of other modalities such as CT for assessment of systemic disease and MRI for the involvement of the CMR. Recent dramatic advances in MRI technology make it the preferred initial local staging choice at many centers, with EUS reserved for determination of T1/T2 staging and when EUS-FNA is desired.

Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

REFERENCES

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017;67:7–30.
2. Glimelius B, Påhlman L, Cervantes A, et al. Rectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21 Suppl 5:v82-6.
3. Beynon J, Foy DM, Temple LN, et al. The endoscopic appearances of normal colon and rectum. Dis Colon Rectum 1986;29:810-3.
4. Marusch F, Koch A, Schmidt U, et al. Routine use of transrectal ultrasound in rectal carcinoma: Results of a prospective multicenter study. Endoscopy 2002;34:385-90.
5. Akasu T, Kondo H, Moriya Y, et al. Endorectal ultrasonography and treatment of early stage rectal cancer. World J Surg 2000;24:1061-6.
6. Puli SR, Bechtold ML, Reddy JB, et al. How good is endoscopic ultrasound in differentiating various T stages of rectal cancer? Meta-analysis and systematic review. Ann Surg Oncol 2009;16:254-65.
7. Marusch F, Ptok H, Sahm M, et al. Endorectal ultrasound in rectal carcinoma – do the literature results really correspond to the realities of routine clinical care? Endoscopy 2011;43:425-31.
8. Ahuja NK, Sauer BG, Wang AY, et al. Performance of endoscopic ultrasound in staging rectal adenocarcinoma appropriate for primary surgical resection. Clin Gastroenterol Hepatol 2015;13:339-44.
9. Herrera-Orellas L, Justiniano J, Castillo N, et al. Metastases in small lymph nodes from colon cancer. Arch Surg 1987;122:1253-6.
10. Spinelli P, Schiavo M, Meroni E, et al. Results of EUS in detecting perirectal lymph node metastases of rectal cancer: The pathologist makes the difference. Gastrointest Endosc 1999;49:754-8.
11. Puli SR, Reddy JB, Bechtold ML, et al. Accuracy of endoscopic ultrasound to diagnose nodal invasion by rectal cancers: A meta-analysis and systematic review. Ann Surg Oncol 2009;16:1255-65.
12. Gleson FC, Clain JE, Papachristou GL, et al. Prospective assessment of EUS criteria for lymphadenopathy associated with rectal cancer. Gastrointest Endosc 2009;69:896-903.
13. Park HH, Nguyen PT, Tran Q, et al. Endoscopic ultrasound-guided fine needle aspiration in the staging of rectal cancer. Gastrointest Endosc 2000;51;AB171.
14. Amin K, Olyaei M, Tawfik O, et al. Endoscopic ultrasound-guided fine needle aspiration as a diagnostic and staging tool for rectal and perirectal lesions—an institutional experience. Ann Diagn Pathol 2013;17:494-7.
15. Knight CS, El-Obeidi MA, Crowe R, et al. Utility of endoscopic ultrasound-guided fine-needle aspiration in the diagnosis and staging of colorectal carcinoma. Diagn Cytopathol 2013;41:1031-7.
16. Harewood GC. Assessment of clinical impact of endoscopic ultrasound on rectal cancer. Am J Gastroenterol 2004;99:623-7.
17. Harewood GC, Wiersema MJ, Nelson H, et al. A prospective, blinded assessment of the impact of preoperative staging on the management of rectal cancer. Gastroenterology 2002;125:24-32.
18. Bipat S, Glas AS, Slors FJ, et al. Rectal cancer: Local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging – A meta-analysis. Radiology 2004;232:773-83.
19. Winter L, Bruhn H, Langreh J, et al. Magnetic resonance imaging in suspected rectal cancer: Determining tumor localization, stage, and sphincter-saving resectability at 3-Tesla-sustained high resolution. Acta Radiol 2007;48:379-87.
20. Gualdi GF, Casciani E, Guadalaxara A, et al. Local staging of rectal cancer with transrectal ultrasound and endorectal magnetic resonance imaging: Comparison with histologic findings. Dis Colon Rectum 2000;43:338-45.
21. Kwock H, Bissett JP, Hill GL. Preoperative staging of rectal cancer. Int J Colorectal Dis 2000;15:9-20.
22. Al-Sukhni E, Milot L, Fruitman M, et al. Diagnostic accuracy of MRI for assessment of T category, lymph node metastases, and circumferential resection margin involvement in patients with rectal cancer: A systematic review and meta-analysis. Ann Surg Oncol 2012;19:2212-23.
23. Mercury Study Group. Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: Prospective observational study. BJM 2006;333:779.
24. Fernández-Esparregó G, Ayuso-Colella JR, Sendino O, et al. EUS and magnetic resonance imaging in the staging of rectal cancer: A prospective and comparative study. Gastrointest Endosc 2011;74:347-54.
25. Muller M, Deb R, Singh R. MRI in T staging of rectal cancer: How effective is it? Indian J Radiol Imaging 2010;20:119-21.
26. Gavioli M, Bagni A, Piccagli I, et al. Usefulness of endorectal ultrasound after preoperative radiotherapy in rectal cancer: Comparison between sonographic and histopathologic changes. Dis Colon Rectum 2000;43:1075-83.
27. Rau B, Hünerbein M, Barth C, et al. Accuracy of endorectal ultrasound after preoperative radiochemotherapy in locally advanced rectal cancer. Surg Endosc 1999;13:980-4.
28. Napoles B, Pujol B, Berger F, et al. Accuracy of endosonography in the staging of rectal cancer treated by radiotherapy. Br J Surg 1991;78:785-8.
29. Vanagas A, Lin DE, Stryker SJ. Accuracy of endoscopic ultrasound for restaging rectal cancer following neoadjuvant chemoradiation therapy. Am J Gastroenterol 2004;99:109-12.
30. Marone P, de Bellis M, Avallone A, et al. Accuracy of endoscopic ultrasound in staging and restaging patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiation. Clin Res Hepatol Gastroenterol 2011;35:66-70.
31. Radovanovic Z, Breberina M, Petrovic T, et al. Accuracy of endorectal ultrasonography in staging locally advanced rectal cancer after preoperative chemoradiation. Surg Endosc 2008;22:2412-5.
32. Waage JE, Loh S, Rasler C, et al. Endorectal ultrasonography, strain elastography and MRI differentiation of rectal adenomas and adenocarcinomas. Colorectal Dis 2015;17:124-31.
33. Zhuang H, Yang ZG, Chen HJ, et al. Time-intensity curve parameters in colorectal tumours measured using double contrast-enhanced ultrasound: Correlations with tumour angiogenesis. Colorectal Dis 2012;14:181-7.